Primary apnea of premature newborns

Also known as: Apnea of Prematurity / Neonatal apneic attack / Neonatal apnoeic attack / Apnoea neonatal / Apnea neonatal / Primary apnoea of premature newborns

DrugDrug NameDrug Description
DB00201CaffeineA methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling.
DrugDrug NamePhaseStatusCount
DB00277Theophylline2 / 3Completed1
DB00201Caffeine3Completed3
DB00201Caffeine3Recruiting1
DB00201Caffeine4Completed1
DB00201Caffeine4Recruiting1
DB00201CaffeineNot AvailableCompleted1
DB00201CaffeineNot AvailableRecruiting2
DB09140OxygenNot AvailableRecruiting1